4/A: Sana Biotechnology Director Mary Agnes Wilderotter Corrects Option Shares Acquisition in Amended SEC Filing

Mary Agnes Wilderotter, a director at Sana Biotechnology, files an amended Form 4 to correct the number of option shares acquired.

Summary

• Mary Agnes Wilderotter, a director of Sana Biotechnology, Inc. [SANA], filed an amended Form 4 with the SEC on July 15, 2024, to correct a clerical error regarding the number of option shares acquired.
• The original filing was made on June 7, 2024.
• The corrected filing pertains to a transaction that occurred on June 6, 2024, where Wilderotter acquired 65,000 stock options with an exercise price of $7.36.
• These options vest and become exercisable on the earlier of June 6, 2025, or immediately prior to the 2025 annual meeting of Sana stockholders, contingent upon continuous service to Sana through that date.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing correcting a clerical error. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies like Sana Biotechnology. It provides transparency to investors regarding the holdings and transactions of company insiders.

Key Dates